Search results for "Randomization"

showing 10 items of 148 documents

Individuell dosiertes Levothyroxin mit 150 µg Jodid versus 100 µg Levothyroxin kombiniert mit 100 µg Jodid: Eine randomisierte Doppelblindstudie

2008

BASIC PROBLEM AND OBJECTIVE Intrathyroid deficiency and the influence of thyroid stimulating hormone (TSH) are the main pathogenetic factors in the development of endemic euthyroid goitre. Goitre reduction is achieved with either administration of levothyroxine, which diminishes hypophyseal TSG production, or of iodide. Aim of this study was to compare the efficacy of treatment with a dose-fixed combination of levothyroxine plus iodide with that of an individualized dosage of levothyroxine plus iodide. PATIENTS AND METHODS After randomization 49 patients with euthyroid goitre (24 women, 25 men, aged 20-43 years) were treated for 12 weeks in a double-blind trial. Patients in group A received…

chemistry.chemical_classificationendocrine systemmedicine.medical_specialtyRandomizationendocrine system diseasesbusiness.industryIodideThyroidLevothyroxineGeneral MedicineGastroenterologyGroup BExcretionBasal (phylogenetics)medicine.anatomical_structurechemistryThyroid-stimulating hormoneInternal medicinemedicinebusinessmedicine.drugDMW - Deutsche Medizinische Wochenschrift
researchProduct

Does better education mitigate risky health behavior? A mendelian randomization study.

2022

Education and risky health behaviors are strongly negatively correlated. Education may affect health behaviors by enabling healthier choices through higher disposable income, increasing information about the harmful effects of risky health behaviors, or altering time preferences. Alternatively, the observed negative correlation may stem from reverse causality or unobserved confounders. Based on the data from the Cardiovascular Risk in Young Finns Study linked to register-based information on educational attainment and family background, this paper identifies the causal effect of education on risky health behaviors. To examine causal effects, we used a genetic score as an instrument for year…

elintavatEconomics Econometrics and Finance (miscellaneous)Health BehaviorMendelian Randomization Analysisruokavaliot3121 Internal medicine3142 Public health care science environmental and occupational healthHealth Risk BehaviorskoulutuskoulutustasotupakointiterveyskäyttäytyminenEducational StatusHumans3111 BiomedicinealkoholinkäyttöFinlandEconomics and human biology
researchProduct

Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms

2010

Background— Cholesteryl ester transfer protein (CETP) inhibitors raise high-density lipoprotein (HDL) cholesterol, but torcetrapib, the first-in-class inhibitor tested in a large outcome trial, caused an unexpected blood pressure elevation and increased cardiovascular events. Whether the hypertensive effect resulted from CETP inhibition or an off-target action of torcetrapib has been debated. We hypothesized that common single-nucleotide polymorphisms in the CETP gene could help distinguish mechanism-based from off-target actions of CETP inhibitors to inform on the validity of CETP as a therapeutic target. Methods and Results— We compared the effect of CETP single-nucleotide polymorphisms …

high-density lipoproteinsEpidemiologyBLOOD-PRESSUREPharmacologyDISEASEchemistry.chemical_compoundDOUBLE-BLINDHigh-density lipoprotein:CIENCIAS MÉDICAS ::Medicina interna [UNESCO]Polymorphism (computer science)Physiology (medical)Cholesterylester transfer proteinGeneticsMedicinegeneticsHigh-density lipoproteinsGENOME-WIDE ASSOCIATIONUNESCO::CIENCIAS MÉDICAS ::Medicina internaPharmacologyHDL CHOLESTEROLbiologybusiness.industryCholesterolTorcetrapib:CIENCIAS MÉDICAS [UNESCO]Genetics ; Pharmacology ; Epidemiology ; High-density lipoproteinsDose–response relationshipBlood pressurechemistryATHEROSCLEROSISUNESCO::CIENCIAS MÉDICASbiology.proteinMENDELIAN RANDOMIZATIONepidemiology; genetics; high-density lipoproteins; pharmacologylipids (amino acids peptides and proteins)epidemiologyTORCETRAPIBpharmacologyCardiology and Cardiovascular MedicinebusinessHIGH-DENSITY-LIPOPROTEINLIPID-LEVELSLipoproteinCirculation
researchProduct

Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized …

2008

Summary Purpose A phase III randomized trial was carried out to compare two schedules of the vinorelbine (VNR)–cisplatin (CDDP) regimen in patients with locally advanced unresectable poor prognosis stage IIIB or metastatic stage IV non-small cell lung cancer. The primary endpoints were overall survival (OS) and analysis of toxicity, while secondary endpoints included response rates, time-to-progression (TTP) and quality of life (QoL). Patients and methods Eligible patients were randomized to receive: (a) VNR 25 mg/m 2 on day 1, 8 and 15 plus CDDP 100 mg/m 2 on day 1 every 4 weeks or (b) VNR 30 mg/m 2 on day 1 and 8 plus CDDP 80 mg/m 2 on day 1 every 3 weeks. All patients were chemotherapy-n…

inorganic chemicalsPulmonary and Respiratory MedicineAdultMaleCancer Researchmedicine.medical_specialtyRandomizationLung NeoplasmsVinorelbineVinblastineGastroenterologyStatistics Nonparametriclaw.inventionRandomized controlled triallawInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesLung cancerProspective cohort studyneoplasmsAgedNeoplasm StagingChi-Square Distributionbusiness.industryVinorelbineMiddle Agedmedicine.diseaseVinblastineSurgeryRegimenLogistic ModelsTreatment OutcomeOncologyItalyDisease ProgressionQuality of LifeFemaleCisplatinbusinessFebrile neutropeniamedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct

Characteristics of clinical trials in rare vs. common diseases: A register-based Latvian study.

2017

Background Conducting clinical studies in small populations may be very challenging; therefore quality of clinical evidence may differ between rare and non-rare disease therapies. Objective This register-based study aims to evaluate the characteristics of clinical trials in rare diseases conducted in Latvia and compare them with clinical trials in more common conditions. Methods The EU Clinical Trials Register (clinicaltrialsregister.eu) was used to identify interventional clinical trials related to rare diseases (n = 51) and to compose a control group of clinical trials in non-rare diseases (n = 102) for further comparison of the trial characteristics. Results We found no significant diffe…

lcsh:MedicineDiseaseGeographical locationslaw.invention0302 clinical medicineRandomized controlled triallawOutcome Assessment Health CareClinical endpointMedicine and Health SciencesRegistrieslcsh:ScienceClinical Trials as TopicMultidisciplinaryDrug MarketingPhase III clinical investigationSurvival RateEuropeOncology030220 oncology & carcinogenesisMeta-analysisComparatorsEngineering and TechnologyPhase II clinical investigationResearch Articlemedicine.medical_specialtyRandomizationDrug Research and DevelopmentResearch and Analysis Methods03 medical and health sciencesRare DiseasesInternal medicinemedicineHumansClinical TrialsEuropean UnionSurvival ratePharmacologybusiness.industrylcsh:RLatviaRandomized Controlled TrialsClinical triallcsh:QClinical MedicinePeople and placesElectronicsbusiness030217 neurology & neurosurgeryRare diseasePloS one
researchProduct

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTOHSCT) IN CLL: FIRST RESULTS OF AN EBMT RANDOMIZED TRIAL COMPARING AUTOTRANSPLANT VERSUS WAIT …

2010

Abstract Abstract 877 This phase-III randomized EBMT-intergroup trial studied the impact of a consolidating autoHSCT vs no consolidation for patients with CLL in Binet stage A progressive, B or C , in CR, nodular PR or VGPR after first or second line therapy. The primary objective was to show that autoHSCT increased the 5-year progression-free survival (PFS) by 30%. Although it had been calculated that 270 patients were to be randomized, the study was terminated by the steering committee in July 2007 due to poor accrual. Here we present a first analysis based on 69% of expected follow-up forms. Results: Between November 2001 and July 2007, 223 patients were enrolled (SFGM-TC/FCLLG n=98, MRC…

medicine.medical_specialtyDisease statusRandomizationbusiness.industrymedicine.medical_treatmentIncidence (epidemiology)ImmunologyCell BiologyHematologyHematopoietic stem cell transplantationBiochemistrySurgerylaw.inventionRandomized controlled triallawInternal medicinemedicineIn patientProgression-free survivalStage (cooking)business
researchProduct

The diabetogenic action of statins — mechanisms and clinical implications

2015

Treatment with statins has transformed primary and secondary prevention of cardiovascular disease (CVD), including thrombotic stroke. Evidence-based data demonstrate the benefits and safety of statin therapy and help to guide clinicians in the management of populations at high risk of CVD. Nevertheless, clinical trials, meta-analyses and observational studies highlight a 10-12% increase in new-onset diabetes mellitus (NODM) among patients receiving statins. The risk further increases with intensive therapy and among individuals with known risk factors for NODM. Mechanisms underpinning this effect are not yet fully understood; however, Mendelian randomization studies suggest that they are re…

medicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiseaseType 2 diabetesIn Vitro Techniques030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistancePharmacotherapyRisk FactorsInsulin-Secreting CellsDiabetes mellitusMendelian randomizationSecondary PreventionAnimalsHumansMedicinecardiovascular diseasesIntensive care medicinebusiness.industrynutritional and metabolic diseasesFeeding BehaviorMendelian Randomization Analysismedicine.diseaseClinical trialDiabetes Mellitus Type 2Cardiovascular DiseasesPhysical therapyHydroxymethylglutaryl CoA ReductasesObservational studyHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistancebusinessRisk Reduction BehaviorNature Reviews Endocrinology
researchProduct

Goserelin acetate to avoid hysterectomy in pre-menopausal women with fibroids requiring surgery

1999

Objective: To obtain information on the efficacy of repeated short cycles of GNRH agonist treatment in order to avoid hysterectomy in near-menopausal women with symptomatic fibroids. Study design: 72 pre-menopausal women (mean age 50 years) with one or more uterine fibroids >10 cm in diameter, symptomatic menorrhagia lasting three months or more and haemoglobin=9 g/dl entered the study. The patients were randomized with ratio of approximately 1:4 to: (a) immediate surgery; or (b) treatment with goserelin acetate. Patients randomized to goserelin acetate received a first cycle of 3.6 mg depot once every 28 days for four months. They were followed-up for three years. If menorrhagia was observ…

medicine.medical_specialtyFibroidsRandomizationUterine fibroidsmedicine.medical_treatmentOvariectomyHysterectomylaw.inventionGonadotropin-Releasing HormoneRandomized controlled triallawmedicineHumansFibroids; Hysterectomy; Medical treatmentMenorrhagiaGynecologyHysterectomyLeiomyomabusiness.industryGoserelinGoserelin AcetateObstetrics and GynecologyMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsSurgeryMenopauseLeiomyomaReproductive MedicinePremenopauseGoserelinFemalebusinessMedical treatmentmedicine.drugHuman
researchProduct

Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation …

2016

Abstract Introduction: IELSG32 is an international randomized phase II trial with 2 key clinical questions in pts with PCNSL. The first question focused on optimal induction therapy, and results of the 1st randomization have demonstrated that MATRix combination (methotrexate (MTX), cytarabine (ARAC), thiotepa, rituximab (R)) is associated with significantly better outcome [Ferreri AJ, et al. Lancet Haematol 2016]. The second question addresses the efficacy and neurotolerability of ASCT, as an alternative to WBRT as consolidation. Herein, we report the results of the 2nd randomization (NCT01011920). Methods: HIV-neg pts 18-70 ys and ECOG PS ≤3 with new histology-proven PCNSL and measurable d…

medicine.medical_specialtyIntention-to-treat analysisRandomizationbusiness.industryImmunologyCell BiologyHematologyThioTEPANeutropeniamedicine.diseaseBiochemistry3. Good health03 medical and health sciences0302 clinical medicineQuality of lifeChemoimmunotherapy030220 oncology & carcinogenesisInternal medicineImmunologymedicineClinical endpointRituximabbusiness030215 immunologymedicine.drugBlood
researchProduct

The Mediterranean diet, plasma metabolome, and cardiovascular disease risk.

2020

Abstract Aims To investigate whether metabolic signature composed of multiple plasma metabolites can be used to characterize adherence and metabolic response to the Mediterranean diet and whether such a metabolic signature is associated with cardiovascular disease (CVD) risk. Methods and results Our primary study cohort included 1859 participants from the Spanish PREDIMED trial, and validation cohorts included 6868 participants from the US Nurses’ Health Studies I and II, and Health Professionals Follow-up Study (NHS/HPFS). Adherence to the Mediterranean diet was assessed using a validated Mediterranean Diet Adherence Screener (MEDAS), and plasma metabolome was profiled by liquid chromatogr…

medicine.medical_specialtyMediterranean dietbusiness.industryIncidence (epidemiology)Hazard ratioDiseaseOdds ratio030204 cardiovascular system & hematologyDiet Mediterranean03 medical and health sciences0302 clinical medicineCardiovascular DiseasesRisk FactorsInternal medicineCohortMendelian randomizationMetabolomemedicineMetabolomeHumans030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesGenome-Wide Association StudyEuropean heart journal
researchProduct